# Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

> **NCT06295159** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 90 (estimated)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV
- Advanced Melanoma
- Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nivolumab + Relatlimab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06295159
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06295159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06295159, "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06295159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*